DREPAMASSE Study - Evaluation of a Newborn Screening for Sickle Cell Disease by Tandem Mass Spectrometry

Clinical Trial
Study Details
Enrollment
1431
Interventions
Description

The analysis of the SCD newborn screening with the MS/MS method from Zentech will be realized after achievement and biological validation of the SCD newborn screening in the usual care pathway. The results will be compared with the method used at the Lille Academic Hospital (CHU Lille) (sub-contractor for SCD newborn screening of Lyon)

Name
SCD newborn screening with the MS/MS method from Zentech
Type
Other
Phase
N/A
Status
COMPLETED
Study ID #
NCT03985501
Study Type
Observational
Summary

Three methods are actually used in newborn screening for sickle cell disease (SCD) in France: isoelectric focusing, high performance liquid chromatography and capillary electrophoresis. New technologies are currently under development such as Matrix Assisted Laser Desorption Ionisation - Time of Flight (MALDI-TOF) and tandem mass spectrometry (MS/MS) using the SpOtOn Diagnostics Reagent Kit available in United Kingdom only.

Zentech company (Liège, Belgium) is developing a package for SCD newborn screening using MS/MS technology. The main objective of the present study will be to compare this new technique with the technique actually used in the hospital center of Lille (sub-contractor for SCD newborn screening of Lyon) and the haemoglobin analysis to test its accuracy (sensitivity and specificity).

Study Overview
Contacts and Locations
Locations
Facility

Groupement Hospitalier Est - Hospices Civils de Lyon
69677 Bron
France

GeoPoint
45.73865, 4.91303
Facility

Hopital de la Croix Rousse
69004, Lyon
France

GeoPoint
45.74906, 4.84789
Facility

Centre Hospitalier Lyon Sud
69495 Pierre-Bénite
France

GeoPoint
45.70359, 4.82424